Profile data is unavailable for this security.
About the company
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
- Revenue in USD (TTM)1.73bn
- Net income in USD599.95m
- Incorporated2011
- Employees2.10k
- LocationAlkermes PlcConnaught House1 Burlington Road, Dublin 4DUBLIN D04 C5Y6IrelandIRL
- Phone+353 17728000
- Websitehttps://www.alkermes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.27bn | 1.28k | -- | 23.31 | -- | 7.39 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.29bn | 352.00 | 29.56 | 6.00 | 27.65 | 6.29 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.35bn | 239.00 | -- | 10.30 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.65bn | 545.00 | -- | 25.29 | -- | 14.52 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Crinetics Pharmaceuticals Inc | 1.97m | -235.46m | 3.70bn | 290.00 | -- | 4.21 | -- | 1,872.02 | -3.77 | -3.77 | 0.0315 | 11.14 | 0.0031 | -- | 0.3653 | 6,806.90 | -35.57 | -42.53 | -37.86 | -45.36 | -- | -- | -11,641.13 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.70bn | 271.00 | 26.54 | 2.24 | 22.83 | 2.92 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 4.02bn | 2.10k | 6.78 | 3.20 | 6.05 | 2.33 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Hims & Hers Health Inc | 959.40m | -2.35m | 4.10bn | 1.05k | -- | 11.89 | 509.74 | 4.28 | -0.016 | -0.016 | 4.46 | 1.61 | 2.33 | 6.68 | -- | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | -- | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Immunovant Inc | 0.00 | -243.45m | 4.13bn | 164.00 | -- | 6.07 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Alvotech SA | 114.39m | -494.28m | 4.24bn | 999.00 | -- | -- | -- | 37.02 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -145.51m | 4.33bn | 106.00 | -- | 6.41 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Krystal Biotech Inc | 95.95m | 57.16m | 4.54bn | 229.00 | 84.48 | 5.68 | 71.59 | 47.33 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Immunitybio Inc | 302.00k | -600.96m | 4.58bn | 628.00 | -- | -- | -- | 15,159.54 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 4.76bn | 376.00 | -- | 5.43 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Data as of May 28 2024. Currency figures normalised to Alkermes Plc's reporting currency: US Dollar USD
59.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 25.66m | 15.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 19.68m | 11.63% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 14.89m | 8.80% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.00m | 5.32% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 8.13m | 4.81% |
| RTW Investments LPas of 31 Mar 2024 | 6.05m | 3.58% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 5.89m | 3.48% |
| Pacer Advisors, Inc.as of 31 Mar 2024 | 4.28m | 2.53% |
| Geode Capital Management LLCas of 31 Mar 2024 | 3.74m | 2.21% |
| Deep Track Capital LPas of 31 Mar 2024 | 3.50m | 2.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
